Table 4

Differences in diisocyanate OA between those developing symptoms 1980–86 and 1987–93

1980–861987–93p Value
*Number with information in the file.
n137288
Age (y, mean (median))40 (38.3)36 (33.9)0.002
Male (%)72550.001
Exposure after onset of symptoms (y, mean (SD (median)))3.03 (3.92 (1.3)2.06 (3.17 (0.83)0.014
Use of inhaled steroids (%)41250.003
FEV1 predicted (%, mean (SD (median)))96 (24 (100)98 (21 (99)NS
VC predicted (%, mean (SD (median)))104 (21 (106)102 (17 (103)NS
FEF50 predicted (%, mean (SD (median)))76 (40 (72.2)88 (33 (90.3)0.03
FEF25 predicted (%, mean (SD (median)))71 (54 (58.8)75 (42 (67.2)NS
Actual FEV1/VC (%, mean (median))72 (73.9)77 (78.5)0.0003
Methacholine PC20 during work period (mg/ml, mean (SD (median)))4.9 (11.1 (0.97)) (42)*4.4 (11.8 (0.8)) (59)*NS
Methacholine PC20 off work (mg/ml, mean (SD (median)))13.2 (18.3 (6.0)) (77)*20.8 (25.3 (8.0)) (162)*0.02